in Newswire January 11, 2018

Lawsuit Claims Allergan Unlawfully Delayed Approval of Generic Alternatives to Restasis [UPDATE]

by Erin Shaak

Last Updated on October 22, 2021

Self Insured Schools of California v. Allergan, Inc

Filed: January 5, 2018 § 8:18cv17

A proposed class action has been filed in California federal court against Allergan, Inc., claiming the drug manufacturer attempted to delay the entrance of generic alternatives to its cyclosporine ophthalmic emulsion drug, Restasis.

Defendant(s)

Allergan, Inc.

Law(s)

State(s)

California

Case Updates

October 22, 2021 – Settlement Proposed for Restasis Buyers

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on October 22, 2021 — 4:49 PM

Erin Shaak

erin@classaction.org

Erin works primarily on ClassAction.org’s newswire, reporting on cases as they happen.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.